Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Lysine acetylation is becoming increasingly recognized as a general biological principle in cellular homeostasis, and is subject to abnormal control in different human pathologies. Here, we describe a global effect on amyloid-like protein aggregation in human cells that results from aberrant lysine acetylation. Bromodomain reader proteins are involved in the aggregation process and, using chemical biology and gene silencing, we establish that p300/CBP bromodomains are necessary for aggregation to occur. Moreover, protein aggregation disturbs proteostasis by impairing the ubiquitin proteasome system (UPS) and protein translation, resulting in decreased cell viability. p300/CBP bromodomain inhibitors impede aggregation, which coincides with enhanced UPS function and increased cell viability. Aggregation of a pathologically relevant form of huntingtin protein is similarly affected by p300/CBP inhibition. Our results have implications for understanding the molecular basis of protein aggregation, and highlight the possibility of treating amyloid-like pathologies and related protein folding diseases with bromodomain inhibitor-based strategies.

Original publication

DOI

10.1016/j.chembiol.2016.11.009

Type

Journal article

Journal

Cell Chem Biol

Publication Date

19/01/2017

Volume

24

Pages

9 - 23

Keywords

CBP, acetylation, aggregation, amyloid, bromodomain, histone deacetylase, huntingtin, inhibitor, p300, proteostasis, Acetylation, Amyloid, Humans, Huntingtin Protein, Lysine, Proteasome Endopeptidase Complex, Protein Aggregates, Protein Aggregation, Pathological, p300-CBP Transcription Factors